Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort Elaine Kunzler, MD, Stephanie Florez-Pollack,

Slides:

Advertisements

Similar presentations

Clavi syphilitici–an unusual presentation of syphilis

Advertisements

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle Kathryn.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Psoriasis is associated with lipid abnormalities at the onset of skin disease Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,

Reactive hemophagocytic syndrome in a patient with adult-onset Still disease Geneviève Gavigan, MASc, MD, Jennifer Beecker, MD, CCFP(EM), FRCP, FAAD

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Alexa B. Kimball,

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Baldness reversed by chemotherapy

Volume 2, Issue 1, Pages 1-3 (January 2016)

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Efficacy of simvastatin in plaque psoriasis: A pilot study

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Ana Corcimaru, BS, Dean S. Morrell, MD, Craig N. Burkhart, MD

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea Jack C. O’Brien, Yevgeniya Byekova Rainwater, Neeta.

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Kishore L. Jayakumar, BS, Sara S. Samimi, MD

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

Reply to: “A note on normality”

Histopathological changes in morphea and their clinical correlates: Results from the Morphea in Adults and Children Cohort V Daniel Walker, MD, Joseph.

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open- label extension study with optional narrow-band ultraviolet.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Infectious rash after riding elephants

Monica Enamandram, BS, Shinjita Das, MD, Keri S. Chaney, MD

Lip edema Journal of the American Academy of Dermatology

Quality of life in pediatric patients before and after cosmetic camouflage of visible skin conditions Michele L. Ramien, MD, Sandra Ondrejchak, RN, Roxanne.

Solomon Shockman, MD, Lauren Krug, MD, Nektarios Lountzis, MD

Hugh Gloster, MD, Chesahna Kindred, MBA

Seasonal patterns in alopecia areata, totalis, and universalis

Medicaid acceptance among pediatric dermatologists

Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients Feriel Fennira, MD, François Chasset, MD, Martin Soubrier,

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Painful violaceus bullae of the hands

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Jules B. Lipoff, MD, Neha Jariwala, BS, Monica Paz, MD, Rudolf R

Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families Lucy Y. Liu,

Jennifer L. Hundley, MD, Christie L

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Yu-Chen Huang, MD, Ying-Chih Cheng, MD

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Gordon W. Jung, MD, Patricia T. Ting, MSc, MD, Thomas G

Minimal improvements in the global burden of skin disease from 1990 to 2013 Jessica Mounessa, Taylor Braunberger, MD, Cory A. Dunnick, MD, Robert P. Dellavalle,

Assessment of dermatology clinic resources at safety-net hospitals: Results from a national survey Neeta Malviya, BS, Joerg Albrecht, MD, Erin Amerson,

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Classification of facial psoriasis based on the distributions of facial lesions Seung Man Woo, MD, Jung Won Choi, MD, Hyun Sun Yoon, MD, Seong Jin Jo,

Morphea in a patient undergoing treatment with ustekinumab

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience Andrew F. Alexis, MD, MPH,

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort Elaine Kunzler, MD, Stephanie Florez-Pollack, BS, Noelle Teske, MD, MSc, Jack O'Brien, MD, Smriti Prasad, BS, Heidi Jacobe, MD, MSCS Journal of the American Academy of Dermatology Volume 80, Issue 6, Pages 1664-1670.e1 (June 2019) DOI: 10.1016/j.jaad.2019.01.050 Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Median quality of life and LoSCAT component scores in linear morphea participants over time. Paired scores were analyzed over a 3-year follow-up period. CDLQI and DLQI scores significantly improved between the baseline and 3-year follow-up study visits (P < .001 and P = .006, respectively). Activity (measured by mLoSSI and PGA-A) decreased significantly over time (P < .001). LoSDI scores showed a trend to increase; however, this did not reach significance (P = .42). Median PGA-D scores minimally decreased from 30 (IQR 20-50) at baseline to 27 (IQR 20-40) at 3-year follow-up (P < .001). CDLQI, Children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; IQR, interquartile range; LoSDI, Localized Scleroderma Damage Index; mLoSSI, modified Localized Scleroderma Skin Severity Index; PGA-A, Physician Global Assessment of Disease Activity; PGA-D, Physician Global Assessment of Disease Damage. Journal of the American Academy of Dermatology 2019 80, 1664-1670.e1DOI: (10.1016/j.jaad.2019.01.050) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 mLoSSI and LoSDI scores in patients with pediatric and adult-onset linear morphea over time. A, Median scores for both groups decreased from baseline to first annual study visit and remained stable. B, LoSDI scores showed a trend to increase over time. LoSDI, Localized Scleroderma Damage Index; mLoSSI, modified Localized Scleroderma Skin Severity Index. Journal of the American Academy of Dermatology 2019 80, 1664-1670.e1DOI: (10.1016/j.jaad.2019.01.050) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions